AzTrials
AzTrials

Plaque Ph Lowering After Use of ProbioticsPhase 4NCT01601145

Effect of Probiotic on the Plaque pH. A Randomized Double Blind Interventional Study

A Phase 4 study testing consumption of lozenges in people with Plaque Ph Lowering After Use of Probiotics and Caries, run by Università degli Studi di Sassari at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the present research protocol was to evaluate the effect of probiotics daily used, on the plaque acidogenicity of children. The null hypothesis was that the plaque acidogenicity would remain unchanged and not associate with the use of probiotics. Read more about this study

Who is it for?
Ages 6 to 8 years
What is being tested?
consumption of lozenges
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
192 participants
Where
1 siteItaly
Study dates
Jan 2012to Aug 2012
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 8 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Written declaration of informed consent signed by parents/guardian
  • At least 20 teeth
  • Good general health, as assessed by investigator
  • Average oral hygiene (cleaning the teeth at least twice a day)
  • Agreement of test subject not to use any oral hygiene products other than the test products and toothpaste provided for the duration of the study; the use of non-fluoridated oral hygiene agents is allowed.
  • Flow rate of stimulated saliva ≥ 0.7 ml/min
  • At least on caries active lesion (d/D>0)

Who cannot join

  • Ongoing oral or dental treatment except for emergency treatment.
  • Known allergic reaction to an oral hygiene product and/or medication and/or dental material previously used in the mouth or pharynx.
  • Existing allergy to one of the components of the test products or the standard toothpaste.
  • Pathological changes of the oral mucosa, e.g. acute ulcerating gingivitis, acute herpetic gingivostomatitis, recurrent aphthous ulceration or systemic illnesses with oral manifestations.
  • Use of fluoride-containing products (pastes, mouthrinses) within the 14 days prior to the introduction of the intra-oral appliances.
  • Use of fluoride-containing products: gels, tablets, varnishes, fillings etc. or of erosive broncholytics or antiasthmatics within 30 days prior to the introduction of the intra-oral specimen holder.
  • Antibiotic therapy within the past six months.
  • Any non-permitted therapy.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • University of Sassari, Dept of Surgery, Microsurtgery and Medicine Sciences

    Sassari, SS, 07100

Other trials in Italy

About this study

The aim of the present research protocol was to evaluate the effect of probiotics daily used, on the plaque acidogenicity of children. The null hypothesis was that the plaque acidogenicity would remain unchanged and not associate with the use of probiotics. Moreover, the in situ study will be carried out to investigate the plaque formation as biofilm in demineralised enamel specimens following the regular consumption of a probiotic product compared to a control group. Metabolic of the biofilm formed on of the enamel specimens resulting from the consumption will be evaluated over a period of 8 weeks.

Read the detailed description

Prior to the start of the study, demographic, ethnic and prognostic data will be collected (screening phase). A medical history will be taken, with documentation of previous and concomitant treatment and a clinical examination of the oral cavity (dental status, oral mucosa) will be performed by the investigator. If the test subject meets all the inclusion criteria without fulfilling any of the exclusion criteria, he/she will be enrolled in the clinical trial and given a test subject identification number.

All test subjects will receive a patient diary in the screening phase.

Washout phase I (1 week):

The test subjects will use only the fluoride-containing toothpaste provided by the sponsor for daily oral hygiene. A soft toothbrush will likewise be provided.

The test subjects will also receive a patient diary which will inform them that during the treatment phase they may not use any fluoride containing oral hygiene products (tooth-paste, mouthwashes, gels etc.) other than the study tooth-paste, drink any fluoride-containing mineral water or black tea, or eat any fish meals.

Treatment phase I (6 weeks):

Following washout phase I, the test subjects start the first treatment phase. Plaque pH measurements at 1 week.

All subjects are instructed about oral hygiene and about the consumption of the study product.

Treatment phase II (1 week after):

The test subjects will use only the fluoride-containing toothpaste provided by the sponsor for daily oral hygiene. A soft toothbrush will likewise be provided. Plaque pH measurements.

  1. MATERIALS AND METHODS 1.1 Clinical parameters DMFT index, gingival index 1.2 Investigation of saliva factors Saliva factors pH and flow rate will be measured during the screening phase on three days, each time in the morning. The mean of the three measurements will be calculated. The Dentobuff® test kit (Vivadent, Liechtenstein) will be used. 1.3 Teeth brushing technique Test subjects are required to clean their teeth three times a day with the fluoride-containing toothpaste and a soft toothbrush. During that time, a fresh, damp gauze (soaked in water) will be placed in the container each day in order to provide a moist atmosphere for the appliances. The specimens should not be allowed to dry out. The enamel specimens themselves are likewise carefully cleaned with the soft toothbrush except the last day of every period. 1.4 Randomization Using a computer program (Excel 2003 for Mac OsX), the randomization will carried out on an individual basis. 1.5 Application of the study product The subjects are not allowed to chew the lozenges. They are allowed to swallow the lozenges. 1.6 Plaque-pH evaluation At the end of each phase plaque acidogenicity will be assessed using the MicroTouch technique after a previous sucrose challenge. Evaluations of pH will be carried out at on each specimen. The pH will be measured in quintuplicate at 6 different time points: at baseline (before sucrose rinse) and 2, 5, 10, 20 and 30 min after a 1-min rinse with 10 ml 10% sucrose, using active movements. An iridium touch microelectrode (diameter 0.1 mm; Beetrode® NMPH-1, World Precision Instruments, Sarasota, Fla., USA, with a porous glass reference electrode (MERE 1, World Precision Instruments) will be used. A salt bridge will be created in a KCl (3 M) solution between the reference electrode and a finger of the subject. Before each session of pH evaluation, the electrode will be calibrated using buffer solution at pH 7.00 and 4.00.
  2. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE 2.1 Planned Analysis Descriptive summary statistics will be computed for all parameters documented in the case report form (CRF).

Quantitative parameters will be described by seven-point scales with mean, standard deviation, median, quartiles, minimum and maximum. Absolute and relative frequencies will be given for qualitative variables. All descriptions will be done separately for treatment groups and visits.

The full statistical analysis including details such as methods of dealing with outliers, missing values, data under prohibited concomitant medication, prohibited nutrition or other possible irregularities will be fixed in a more detailed statistical analysis plan, which will be updated during a blind review of the data before applying the randomisation code to the data for the final analysis.

In order to ensure that the database accurately reflects the data reported in the CRF, a double data entry procedure (data entered by different staff in two separate data files) will be used. In addition to an electronic comparison of these two data files a validation of the data will check ranges, consistency and plausibility. Unclear data will undergo a data cleaning process ("queries"). Any changes applied to data in the database during data cleaning will be recorded in a special log file. The database will be frozen on completion of data cleaning.

Appropriate validated software (e.g. SAS, SPSS) will be used for the data processing and statistical evaluation.

Confirmative statistical testing For confirmative statistical testing an analysis of variance (ANOVA) model will be used as a global test, including the treatment sequences as "between subject factors" and the treatment conditions as "within subject factors".

The full analysis will be described in detail in a specific statistical analysis plan before unblinding the data.

Adjustment of type I error due to multiple testing is not necessary due to a prior ordering of the hypotheses. Hypothesis testing has to be stopped if a null-hypothesis may not be rejected at the 5% error level α. This procedure maintains a constant global level of α = 5%.

Being tested
consumption of lozenges
Keywords
Lactobacillus Brevis CD2, schoolchildren, dental caries, Gingivatis
Medical subject headings
Gingivitis, Dental Caries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • consumption of lozengesDietary supplement

    Each subject two lozenges a day for 6 weeks

Study groups in NCT01601145
Study groupRoleWhat they receive
lozenges with Lactobacillus brevis CD2ExperimentalRandomized group using lozenges for 6 weeks.
Receives: Dietary Supplement: consumption of lozenges
lozengesPlacebo comparatorRandomized group using lozenges for 6 weeks.
Receives: Dietary Supplement: consumption of lozenges

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lower plaque acidogenicity

    The regular consumption of probiotic will lead to a significantly lower plaque acidogenicity compared to a placebo. Regular oral hygiene is permitted.

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2012 (estimated)
  2. Study startJan 2012
  3. Primary completionJul 2012
  4. Study completionAug 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
192 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01601145
Sponsor's protocol ID
146/2011
Status last verified
Aug 2012
First submitted
15 May 2012
Last updated
22 Aug 2012
Results posted
No
Data monitoring committee
No

Publications

  • Campus G, Cocco F, Carta G, Cagetti MG, Simark-Mattson C, Strohmenger L, Lingstrom P. Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren. Clin Oral Investig. 2014;18(2):555-61. doi: 10.1007/s00784-013-0980-9. Epub 2013 May 5.

    PubMed 23644602

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing consumption of lozenges in people with Plaque Ph Lowering After Use of Probiotics and Caries, run by Università degli Studi di Sassari at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Aug 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lower plaque acidogenicity (time frame: 2 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01601145, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in